Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that combining liraglutide with metformin led to greater weight loss and waist circumference reduction than either treatment alone in obese women with PCOS resistant to metformin monotherapy.

This correspondence about the treatment of chronic alopecia areata with tildrakizumab reports no clinical results; the authors present an open-label pilot study setup.

Phenytoin, a medication, can cause hair loss and trigger a condition similar to lupus.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

This study found that ritlecitinib, approved for alopecia areata in patients aged 12 and older, has an acceptable safety profile with mild to moderate side effects and no increase in serious adverse events compared to placebo.

This meta-analysis reports that ritlecitinib significantly improved hair growth in alopecia areata patients compared to placebo, although its potential requires further clinical exploration.

This study found that treatment with ritlecitinib improved hair regrowth in alopecia areata patients, with many achieving significant results after 24 weeks compared to placebo.

This study found that among anti-TNF-α agents, certolizumab is the least likely to cause paradoxical reactions such as psoriatic alopecia and appears to be an effective and safe option for managing psoriasis and PsA while minimizing these risks.

This study observed that topiramate treatment in female zebrafish may impair genetic transmission to offspring, reducing expression of certain skeletal development-related genes in embryos.

This study found that LY320236 is a competitive inhibitor of type I and a non-competitive inhibitor of type II steroid 5alpha-reductase, indicating its potential as a dual inhibitor with differing modes of activity.

Flutamide helps with prostate cancer and some skin conditions but can harm the liver.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

In this case report, a patient with HIV developed hirsutism after starting tofacitinib for alopecia areata, which resolved upon medication discontinuation and laser hair removal.

This case report details a 45-year-old woman with SLE who experienced severe leukopenia and hair loss attributed to azathioprine, suggesting the importance of recognizing these potential adverse effects for timely intervention.

In this prospective study, ritlecitinib effectively reduced hair loss in patients with severe alopecia areata, with 43.3% of participants achieving a 20 or lower SALT score by week 24, and showed a good midterm safety profile.

In this case report, a young adult male with resistant alopecia areata showed nearly 90% hair regrowth after 3 months of treatment with tofacitinib, alongside biotin supplementation, without any side effects observed.

Deuruxolitinib is generally safe for treating alopecia areata.

This article discusses Fluxactive Complete, a natural supplement for prostate health, and reports no new clinical results.

In this report, a patient with vitiligo and systemic lupus erythematosus achieved complete skin repigmentation after 30 days of treatment with the oral JAK inhibitor tofacitinib, with no adverse reactions, suggesting its efficacy and safety as a potential treatment for vitiligo with coexisting autoimmune conditions.

This case report describes a 23-year-old Asian woman with fluoxetine non-responsive trichotillomania who showed significant improvement with bupropion and cognitive behavior therapy, though confirmation in larger trials is needed.

This study found that Janus kinase inhibitors were effective in inducing clinical and biochemical remission in patients with Ulcerative Colitis while exhibiting an expected safety profile, though 30% discontinued treatment due to adverse events or lack of efficacy.

This study observed that simvastatin promoted hair regrowth in a mouse model of alopecia areata by reducing inflammatory markers and T cell proliferation, partly through disruption of isoprenoid metabolite production.

The trial is ongoing, but researchers are evaluating the efficacy and safety of REZPEG, a potential new therapy for severe alopecia areata, which selectively expands regulatory T cells.

This case report documents what may be the second reported instance of azithromycin-induced agranulocytosis, highlighted by a sudden drop to zero in absolute neutrophil count in a 67-year-old man.